On June 3, 2025, Elicio Therapeutics entered into a $10 million Senior Secured Promissory Note agreement due June 3, 2028, to fund working capital, facilitated by GKCC, LLC, a board member’s entity; interest will be at Prime Rate plus 5% (max 12.5%).